论文部分内容阅读
盐酸苯扎普利(benazepril hydrochloride)系美国汽巴嘉基公司开发的无SH基血管紧张素转化酶(ACE)抑制剂。为前体药物,在体内水解为二酸体的benazeprilat,从而达到血管紧张素转化酶抑制作用。动物实验表明,本品起效快,作用持续时间长。本品对ACE特异性强,血压正常的大鼠口服后,对血管紧张素Ⅰ的升压抑制效果与依那普利一样。 62例轻～中等症原发性高血压患者初期给予本品每日1次2.5 mg,每隔2周逐渐增量至5mg或10mg或20mg,达到理想的降压效果后保持用量,共给药10周,结果,除不能判定外,降压率为87.5％。不同给药量的累积降压率在初次量2.5mg为26.8％,
Benazepril hydrochloride is a SH-free angiotensin-converting enzyme (ACE) inhibitor developed by the American Ciba-Geigy Corporation. As a prodrug, benazeprilat is hydrolyzed to the diacid in the body to achieve angiotensin-converting enzyme inhibition. Animal experiments show that the rapid onset of this product, the role of long duration. The product of ACE-specific, normal blood pressure in rats after oral administration, the inhibitory effect of angiotensin I and enalapril. 62 patients with mild to moderate essential hypertension in patients with initial administration of this product once daily 2.5 mg, every 2 weeks gradually increased to 5mg or 10mg or 20mg, to achieve the desired effect of antihypertensive effect, co-administration 10 weeks, the result, except can not judge, the buck rate was 87.5%. The cumulative dose-lowering rate of different doses of 2.5mg in the initial amount of 26.8%